
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc. is poised for significant revenue growth, particularly with Giapreza, which addresses a substantial unmet need in septic shock management, expected to gain traction with updated treatment guidelines. Following the launch of Xacduro, sales projections indicate a robust upward trend, with anticipated revenue of approximately $21.1 million in 2024 and a notable run rate of $95.3 million by 2025. Additionally, the company's emphasis on expanding its portfolio, supported by strong sales growth and durable patent protection for its key products, reinforces Innoviva's commercial momentum and positive market outlook.
Bears say
Innoviva Inc faces significant challenges that underlie a negative outlook regarding its stock performance, primarily due to the severe health risks associated with multidrug-resistant pathogens, which could impede the successful commercialization of its products. The company confronts multiple risks that include potential failures in launching key products, increased competition from generic alternatives, and the possibility of partnership issues, all of which threaten revenue stability. Additionally, macroeconomic factors and investment value declines further exacerbate Innoviva's financial vulnerabilities, potentially hindering growth prospects and shareholder return.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares